BEAM today
$23.23-$0.80 (-3.31%)close Nov 13, 2026Trend
DailyDowntrend (confirmed)
4 hourStrong Bearish
1 hourStrong Bearish
15 minStrong Bearish
5 minBearish
Daily trend turns up above $31.48
Key levels
Resistance$26.94
Resistance$24.88
Support$23.16
Support$20.23
Latest news & SEC filings
AnalystWedbush keeps Outperform on Beam Therapeutics, lifts target to $33
ProductBeam Therapeutics reports encouraging results from Phase 1/2 BEACON study of risto-cel
All BEAM news →About Beam Therapeutics
Beam Therapeutics is a biotechnology company creating precision genetic medicines through a method that chemically alters individual DNA letters without cutting both strands of the helix. Its development programs address sickle cell disease, a inherited liver protein disorder, a metabolic glycogen storage condition, and a metabolic disease involving phenylalanine buildup, delivered either by modifying cells outside the body or by lipid nanoparticles inside the body. The company also runs a manufacturing site in North Carolina.
Based on the company's 10-K filed Feb 24, 2026.
Nasdaq · Healthcare
Beam Therapeutics Inc. (BEAM)
What Is the Price Target for BEAM?
SEPT Low Target
$28.00
SEPT Mid Target
$73.50
SEPT High Target
$80.00
Analyst Consensus
$73.50
Is BEAM a Buy or Sell Right Now?
Thesis
- •Revenue growing 120.0% YoY with STRONG trend — consistent growth.
AI-Powered Trading Signals
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy for BEAM.
Start Free Trial →Is BEAM Overvalued or Undervalued?
Valuation Verdict
UNDERVALUED
Methods Used
P/B, Analyst Consensus
Fair Value
$61.64
25
Moat Score
NONE
4/9
Piotroski Score
5.3
Altman Z-Score
What Is Smart Money Doing with BEAM?
Insider Signal
SELLING
0 buys / 9 sells (90d)
Congress Signal
NEUTRAL
0 buys / 0 sells (90d)
Institutional
N/A
Short Squeeze Risk
HIGH
Signal: HIGH_SHORT_INTEREST
Recent Insider Activity
| Name | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
| Evans John M. | director officer | Buy | 25,000 | $26K | Oct 16, 2026 |
| Evans John M. | director officer | Sale | 25,000 | $600K | Oct 16, 2026 |
| Evans John M. | director officer | Buy | 25,000 | $26K | Oct 15, 2026 |
| Evans John M. | director officer | Sale | 25,000 | $589K | Oct 15, 2026 |
| Ciaramella Giuseppe | officer | Sale | 123,407 | - | Sep 24, 2026 |
Track Smart Money Across 4,000+ Stocks
Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.
See All Smart Money Signals →BEAM Growth Story
Revenue YoY
120.0%
3yr Revenue CAGR
31.9%
EPS Growth YoY
82.31%
FCF Growth YoY
-1.1%
Revenue Trend
STRONG
Dark Pool Trades for BEAM
PREVIEWSEPT Investing tracks real-time dark pool institutional trades for BEAM, including block trade sizes, dollar values, and buy/sell side classification. Dark pool trades reveal where institutional investors are positioning before moves become visible on public exchanges.
| Time | Price | Size | Value | Side |
|---|---|---|---|---|
| 18:15:23 | $23.23 | 4,000 | $$93K | BUY |
| 18:11:51 | $23.21 | 2,154 | $$50K | BUY |
| 18:11:42 | $23.22 | 2,000 | $$46K | MIDPOINT |
| 18:00:37 | $23.34 | 1,000 | $$23K | SELL |
| 18:00:37 | $23.36 | 1,000 | $$23K | BUY |
5 dark pool trades shown · $$236K preview volume
Real-time institutional flow, block trades, and net positioning
Options Flow for BEAM
PREVIEWSEPT Investing provides real-time options flow tracking for BEAM, including unusual sweep detection, block trades, and dealer positioning. Each trade shows strike, expiry, premium, implied volatility, and greek values for informed decision-making.
| Type | Strike | Expiry | DTE | Premium | Size | Trade |
|---|---|---|---|---|---|---|
| PUT | $22 | Dec 18 | 35 | $$240 | 2 | SWEEP |
| CALL | $25 | Jan 21 | 434 | $$720 | 1 | SWEEP |
| CALL | $25 | Jan 21 | 434 | $$720 | 1 | SWEEP |
| CALL | $25 | Jan 21 | 434 | $$720 | 1 | SWEEP |
| CALL | $20 | Jan 21 | 434 | $$900 | 1 | SWEEP |
5 options trades shown · 80% calls
Unusual activity, GEX levels, max pain, and dealer positioning
What Traders Are Saying About BEAM
2 postsSEPT Investing hosts an active community of 3,500+ traders sharing real-time analysis, trade setups, and market discussion for BEAM. Join verified traders discussing price action, dark pool alerts, options flow, and AI-powered market intelligence.
Zone Setup — $BEAM (Beam Therapeutics Inc.) Price: $25.90 | Zone: $25.68 — $26.66 Conviction: HIGH | Analyst upside: +77.4% Near support (23% of range) — reversal watch. Strong positive news (1+ vs ...
Zone Setup -- $BEAM (Beam Therapeutics Inc.) Price: $44.75 | Zone: $42.30 to $45.55 Conviction: HIGH | Analyst upside: +63% Near resistance (75% of range) — breakout watch. Earnings: DOUBLE_BEAT. Ea...
Join 3,500+ traders discussing BEAM in real-time
Trade ideas, setups, dark pool alerts, and AI-powered analysis
Full AI Research Report
SEPT's Trading AI has generated a free, downloadable PDF research report for Beam Therapeutics Inc. (BEAM) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.
Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (1 articles analyzed), and SEC filing intelligence...
AI-Powered Trading Signals.
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy. SEPT tells you when to buy, when to sell, and grades every stock so you never trade blind.
Try SEPT Free for 7 Days →BEAM — frequently asked questions
What is BEAM stock price today?
Beam Therapeutics Inc. (BEAM) is at $23.23, down 3.31% (-$0.80) at the Nov 13, 2026 close.
Why is BEAM stock moving today?
Latest BEAM news — Nov 11, 2026: Wedbush keeps Outperform on Beam Therapeutics, lifts target to $33 · Nov 10, 2026: Beam Therapeutics reports encouraging results from Phase 1/2 BEACON study of risto-cel
What is the BEAM price target?
The average analyst price target for BEAM is $73.50, ranging from $28 to $80, based on 6 analysts. Latest: Canaccord Genuity maintains on Oct 29, 2026.
What do analysts rate BEAM?
Analyst ratings for BEAM: 0 Buy, 10 Hold, 0 Sell — consensus Hold.
Did BEAM beat earnings?
BEAM last reported on Aug 4, 2026: EPS -$1.18 vs -$1.11 expected — a miss of 6.3%.
Does BEAM pay a dividend?
BEAM does not currently pay a dividend.
How much debt does BEAM have?
Beam Therapeutics Inc. reported $100M of debt and $220M of cash (Jun 30, 2026).
What are BEAM support and resistance levels?
Support: $23.16, $20.23. Resistance: $24.88, $26.94, $29.76.
What are insiders doing with BEAM?
Insider activity: SELLING, 0 buys and 9 sells in the last 90 days.
What is the latest news on BEAM?
Nov 11, 2026: Wedbush keeps Outperform on Beam Therapeutics, lifts target to $33 · Nov 10, 2026: Beam Therapeutics reports encouraging results from Phase 1/2 BEACON study of risto-cel